Why 400 Patients ≠ a Small Problem: The Time-Value Economics of Ultra-Rare Disease.

Patient count is a misleading metric for disease burden. When measured in life-years lost, ultra-rare pediatric diseases like progeria rival the burden of cancers affecting thousands.

The 400-Patient Question

Every rare disease company hears the same question: "How big is your market?"

For Hutchinson-Gilford Progeria Syndrome (HGPS), the answer sounds devastating. Roughly 400 children are living with progeria worldwide. The condition occurs in approximately 1 in 18 million births. By any conventional metric, this is as small as a patient population gets.

But patient count is the wrong metric. Here's why.

The Metric That Matters: Life-Years Lost

A child with progeria dies, on average, at 14.5 years old. Against a global life expectancy of 73 years, each patient loses 58.5 life-years — nearly an entire lifetime.

This number is extraordinary. For context, here is how HGPS compares to other conditions in terms of life-years lost per death:

HGPS sits at the extreme end of this spectrum. No other condition combines such a young age of death with complete loss of productive life potential.

The Aggregate Surprise

When we multiply across the patient population:

400 patients × 58.5 life-years = 23,400 life-years lost

To put that number in perspective: 23,400 life-years is equivalent to 7,800 pancreatic cancer deaths. Four hundred children and nearly eight thousand adults — the same amount of human time disappears.

Or consider it another way. The UK reports approximately 2,400 mesothelioma deaths annually (Occupational and Environmental Medicine, WHO data). The total life-years lost from those 2,400 deaths is roughly 7,200. The 400 progeria patients globally lose more than three times that amount.

The lesson is simple. Patient count measures the breadth of a disease. Life-years lost measures its depth. Ultra-rare pediatric diseases are shallow in breadth but bottomless in depth.

The 7× Acceleration Problem

There is a second dimension that standard metrics miss entirely. HGPS is characterized by aging at up to seven times the normal rate (PMC, Rare case of longevity in HGPS, 2025). A child with progeria doesn't just lose years at the end of life — they lose them at an accelerated rate throughout their short life.

This creates a brutal asymmetry in the cost of delayed treatment:

Every year that passes without a new treatment option is not one year lost for these patients. It is seven.

Why This Matters for Drug Repurposing

This acceleration makes the strategic case for drug repurposing in progeria nearly self-evident.

De novo drug development takes 12–15 years on average. For a child aging at seven times the normal rate, that timeline translates to 84–105 biological years of accumulated damage. Most patients will not survive to see the result.

Drug repurposing — identifying new therapeutic applications for existing approved drugs — compresses the timeline to 3–6 years by leveraging established safety profiles and regulatory shortcuts like the FDA's 505(b)(2) pathway. The difference of 7–9 calendar years represents 49–63 biological years of prevented damage per patient.

Across 400 patients, that gap is not marginal. It is the difference between a treatment arriving in time and arriving too late.

The Current Landscape

Today, there is exactly one FDA-approved treatment for progeria: lonafarnib (Zokinvy), approved in November 2020. Clinical data showed a 2.5-year survival benefit and a 60% reduction in mortality over up to 11 years of follow-up (FDA Approval Summary, Genetics in Medicine, 2022).

Lonafarnib is a farnesyltransferase inhibitor — it slows the accumulation of the toxic protein progerin but does not address the underlying mutation. As the Progeria Research Foundation states: it is a treatment, not a cure.

Gene editing approaches, particularly adenine base editing (ABE), have shown extraordinary promise in mouse models — doubling lifespan by directly correcting the causative mutation (Nature, 2021). The Progeria Research Foundation announced a formal Gene Editing Program in 2025. But these therapies remain in preclinical stages, and the path from mouse model to FDA approval historically takes a decade or more.

Between lonafarnib (available now, incomplete efficacy) and gene therapy (potentially curative, years away), there is a gap. Drug repurposing — computationally identifying approved drugs that may reverse the downstream transcriptomic effects of progeria — occupies precisely this gap. It is not a competitor to gene therapy. It is a bridge.

Beyond Progeria

The time-value framework applies far beyond HGPS. Any pediatric rare disease with early mortality and limited treatment options exhibits the same pattern: a small patient count masking an outsized burden when measured in life-years lost.

Duchenne Muscular Dystrophy (~20,000 patients, ~47 LYL each), Spinal Muscular Atrophy, Batten Disease, and hundreds of other conditions share this structural undercount. The 7,000+ rare diseases that still lack any approved treatment collectively affect 300–400 million people — but the youngest and most severe among them carry a per-patient burden that rivals or exceeds common cancers.

When we allocate research dollars, set regulatory priorities, or evaluate investment opportunities, patient count is a starting point. It should not be the ending point. The question is not how many patients but how many years.